Comparison across anti‐amyloid antibodies indicates utility of p‐tau and GFAP as biomarkers of amyloid plaque removal while NfL and tau PET seem unsuitable as consistent indicators of clinical efficacy. The gene discussed is NEFL; the disease is amyloidosis.